Clinical Trials

Radiation Therapy 

Title: A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer 
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11824.

Title: Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12390.

Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck. Sponsor: SciClone.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11810.

For Metastatic Brain Cancer

Neurology/Oncology
Title: (GLIA-001) A Phase 2, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus Gliadel® Wafer in patients with Metastatic Brain Cancer. MGI PHARMA.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11590.

 

Hematology

Title: An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG-531 in Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP). AMGEN.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11765.

For Myleodysplastic Syndrome
Title: A Prospective, Non-Interventional Multicenter Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients. NOVARTIS.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11658.

Title: A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS). AMGEN.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11782.

For Lymphoma
Title: A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE® (bortezomib) in Combination with Rituximab, Cyclophosphmide and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma. Millenium Pharmaceuticals.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11913.

For Chronic Myelogenous Leukemia
Title: A Worldwide Observational Registry collecting Longitudinal Data on the management of Chronic Myelogenous Leukemia (CML) patients (The WORLDCML Registry) in routine practice. Novartis WORLD.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11639.

For Multiple Myleoma
Title: A Randomized, Blinded, Placebo-controlled, Multicenter, Phase II Study of Bevacizumab in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma. GENENTECH.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11164.

Title: Bone Marker directed dosing of ZOMETA® (zoledronic acid) for the prevention of skeletal complications in patients with advanced multiple myeloma. Novartis.
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11698.

  

For information about these or any other clinical trials available at Temple University Hospital Cancer Center, please call the Research Office at 215-707-7471.